EP-1215 Fibroblast Activating Protein specific PET for advanced target volume delineation in Glioblastoma

Windisch, Paul; Röhrich, Manuel; Regnery, Sebastian; Tonndorf-Martini, Eric; Held, T.; Lang, Kristin; Bernhardt, Denise; Rieken, Stefan; Haberkorn, Uwe; Debus, John R.; Adeberg, Sebastian

doi:10.1016/s0167-8140(19)31635-4

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than half the studies were conducted in China. The included studies focused on gastrointestinal cancers (12,(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31), head and neck cancer (11,(32)(33)(34)(35)(36), various cancers (9,10,(37)(38)(39)(40)(41), lung cancer (42,43), sarcoma (44,45), breast cancer (46), lymphoma (47), multiple myeloma (48), glioblastoma (49), and liver metastases (50,51). PET/CT was used as the index test imaging modality in 34 stud-PET/MRI was used in 3 studies, and both PET/CT and PET/ MRI were used in 2 studies.…”

Section: Systematic Reviewmentioning

confidence: 99%

Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis

Wass,

Clifford,

Subramaniam

2023

J Nucl Med

View full text Add to dashboard Cite

Fibroblast-activation protein is a promising target for oncologic molecular imaging. Studies show that fibroblast activation protein inhibitor (FAPI) radiotracers are accurate diagnostics with favorable tumor-tobackground ratios across various cancers. Therefore, we performed a systematic review and metaanalysis to assess the diagnostic performance of FAPI PET/CT in comparison with [ 18 F]FDG PET/CT, the most widely used radiotracer in oncology. Methods: We conducted a systematic search in MEDLINE, Embase, Scopus, PubMed, Cochrane Central Register of Controlled Trials, relevant trial registries, and bibliographies. The search consisted of combinations of terms for 3 topics: neoplasia, PET/CT, and FAPI. Two authors independently screened retrieved articles using predefined inclusion and exclusion criteria and extracted the data. Study quality was assessed using the criteria of QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2). For each study, the sensitivity, specificity, and 95% CIs were calculated to determine diagnostic accuracy for primary, nodal, and metastatic lesions. A random-effects metaanalysis was used for pooling the data, and heterogeneity was assessed (I 2 index). Results: Thirtynine studies (1,259 patients) investigating the use of FAPI PET/CT were included. On a patient-based analysis, pooled sensitivity was 0.99 (95% CI, 0.97-1.0) for the detection of primary lesions. Pooled sensitivity for nodal and distant metastases was 0.91 (95% CI, 0.81-0.96) and 0.99 (95% CI, 0.96-1.0), respectively. On a paired analysis between FAPI and [ 18 F]FDG PET/CT, FAPI had a higher sensitivity in the detection of primary, nodal, and metastatic lesions (all P , 0.001). The differences in sensitivities between FAPI and [ 18 F]FDG were statistically significant. In terms of heterogeneity, analyses on primary lesions were moderately affected, distant metastatic lesions were highly affected, and the nodal metastatic analyses had negligible heterogeneity. Conclusion: The diagnostic performance of FAPI PET/CT is superior to that of [ 18 F]FDG in the detection of primary, nodal, and distant metastases. However, further studies are needed to better evaluate its utility and indication in specific cancer types and clinical settings.

show abstract

Section: Systematic Reviewmentioning

confidence: 99%

Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis

Wass,

Clifford,

Subramaniam

2023

J Nucl Med

View full text Add to dashboard Cite

show abstract

Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review

et al. 2022

View full text Add to dashboard Cite

Rationale This systematic review aims to synthesise the outcomes of different strategies of incorporating functional biological markers in the radiation therapy plans of patients with glioblastoma to support clinicians and further research. Methods The systematic review protocol was registered on PROSPERO (CRD42021221021). A structured search for publications was performed following PRISMA guidelines. Quality assessment was performed using the Newcastle–Ottawa Scale. Study characteristics, intervention methodology and outcomes were extracted using Covidence. Data analysis focused on radiation therapy target volumes, toxicity, dose distributions, recurrence and survival mapped to functional image-guided radiotherapy interventions. Results There were 5733 citations screened, with 53 citations (n = 32 studies) meeting review criteria. Studies compared standard radiation therapy planning volumes with functional image-derived volumes (n = 20 studies), treated radiation therapy volumes with recurrences (n = 15 studies), the impact on current standard target delineations (n = 9 studies), treated functional volumes and survival (n = 8 studies), functionally guided dose escalation (n = 8 studies), radiomics (n = 4 studies) and optimal organ at risk sparing (n = 3 studies). The approaches to target outlining and dose escalation were heterogeneous. The analysis indicated an improvement in median overall survival of over two months compared with a historical control group. Simultaneous-integrated-boost dose escalation of 72–76 Gy in 30 fractions appeared to have an acceptable toxicity profile when delivered with inverse planning to a volume smaller than 100 cm$$^3$$ 3 . Conclusion There was significant heterogeneity between the approaches taken by different study groups when implementing functional image-guided radiotherapy. It is recommended that functional imaging data be incorporated into the gross tumour volume with appropriate technology-specific margins used to create the clinical target volume when designing radiation therapy plans for patients with glioblastoma.

show abstract

EP-1215 Fibroblast Activating Protein specific PET for advanced target volume delineation in Glioblastoma

Cited by 2 publications

References 0 publications

Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis

Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis

Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review

Contact Info

Product

Resources

About